CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Aplagon is developing a targeted therapy called APAC for advanced peripheral arterial occlusive disease (PAOD), focusing on reducing inflammation and preventing further artery damage. The product aims to improve treatment outcomes for patients suffering from severe cardiovascular issues related to atherosclerosis.
There is a major unmet need for effective and safe therapies for advanced peripheral arterial occlusive disease (PAOD) due to the high cardiovascular mortality, morbidity, and amputation rates in these patients.
Aplagon is developing the first vascular injury -targeting product (APAC) for the local treatment of advanced PAOD. PAOD is caused by fatty deposits in lower limb arteries (atherosclerosis) that become inflamed (thromboinflammation), resulting in blood coagulation (atherothrombosis). APA…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
